105 related articles for article (PubMed ID: 20923042)
1. Metabolic effects of hormone deprivation therapy: weighing the evidence.
Van Londen GJ; Lembersky BC
Oncology (Williston Park); 2010 Aug; 24(9):846-7. PubMed ID: 20923042
[No Abstract] [Full Text] [Related]
2. Considering metabolic effects when making breast cancer treatment decisions.
Ligibel JA
Oncology (Williston Park); 2010 Aug; 24(9):844-6. PubMed ID: 20923041
[No Abstract] [Full Text] [Related]
3. Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies.
Dalla Volta A; Mazziotti G; Maffezzoni F; Grisanti S; Palumbo C; Pedersini R; Maroldi R; Berruti A
J Clin Oncol; 2020 Oct; 38(29):3363-3366. PubMed ID: 32603244
[No Abstract] [Full Text] [Related]
4. [Treatment effect of breast cancer and prostate cancer on bone].
Varsavsky M; Guadalix Iglesias S
Med Clin (Barc); 2013 Feb; 140(4):164-8. PubMed ID: 22841464
[TBL] [Abstract][Full Text] [Related]
5. Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy.
Redig AJ; Munshi HG
Oncology (Williston Park); 2010 Aug; 24(9):839-44. PubMed ID: 20923040
[TBL] [Abstract][Full Text] [Related]
6. [Anti-aromatase acting drugs].
Diedrich K
Krankenpfl J; 2005; 43(4-6):150-1. PubMed ID: 16171094
[No Abstract] [Full Text] [Related]
7. Obesity and endocrine therapy: host factors and breast cancer outcome.
Goodwin PJ
Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
[TBL] [Abstract][Full Text] [Related]
8. Cancer treatment-induced bone loss in breast and prostate cancer.
Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant endocrine therapy for breast cancer.
Rao RD; Cobleigh MA
Oncology (Williston Park); 2012 Jun; 26(6):541-7, 550, 552 passim. PubMed ID: 22870539
[TBL] [Abstract][Full Text] [Related]
10. Weighing up the risks and benefits of androgen deprivation therapy.
Rees J
Practitioner; 2014 May; 258(1771):5. PubMed ID: 25055405
[No Abstract] [Full Text] [Related]
11. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
12. Gynecomastia in patients with prostate cancer: update on treatment options.
Autorino R; Perdonà S; D'Armiento M; De Sio M; Damiano R; Cosentino L; Di Lorenzo G
Prostate Cancer Prostatic Dis; 2006; 9(2):109-14. PubMed ID: 16432533
[TBL] [Abstract][Full Text] [Related]
13. Metastatic breast cancer.
Stevanovic A; Lee P; Wilcken N
Aust Fam Physician; 2006 May; 35(5):309-12. PubMed ID: 16680209
[TBL] [Abstract][Full Text] [Related]
14. Reply to K.I. Pritchard.
Fontein DB; van de Velde CJ;
J Clin Oncol; 2013 Dec; 31(35):4477-9. PubMed ID: 24190123
[No Abstract] [Full Text] [Related]
15. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
16. Information Concerning Endocrine Therapy and Adherence of Patients with Breast and Prostate Cancer.
Linke B; Liebl P; Marten D; Stoll C; Jung B; Wuensch P; Huebner J
Clin Oncol (R Coll Radiol); 2015 Aug; 27(8):482-3. PubMed ID: 25869258
[No Abstract] [Full Text] [Related]
17. The importance of nonpharmacogenetic factors in endocrine therapy.
McCowan C; Thompson AM
Pharmacogenomics; 2012 Apr; 13(6):721-8. PubMed ID: 22515614
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
Wheler J; Johnson M; Seidman A
Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347
[TBL] [Abstract][Full Text] [Related]
19. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
Litsas G
Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
[TBL] [Abstract][Full Text] [Related]
20. Adherence to long-term adjuvant hormonal therapy for breast cancer.
Gotay C; Dunn J
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
